Oct 27, 2020
Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
Oct 27, 2020
Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
May 29, 2020
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
May 26, 2020
Exact Sciences to participate in June investor conferences
May 06, 2020
Exact Sciences Announces First Quarter 2020 Results
May 04, 2020
Exact Sciences to participate in May investor conference
Apr 02, 2020
Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth
Mar 19, 2020
Exact Sciences Takes Action during COVID-19 Pandemic
Mar 11, 2020
Fight Colorectal Cancer Receives Grant from Exact Sciences to Launch Program Aimed at Reducing Patient Barriers to Colorectal Cancer Screening
Mar 03, 2020
Exact Sciences Extends Leadership In Advanced Cancer Diagnostics With Acquisitions Of Paradigm And Viomics
Feb 11, 2020
Exact Sciences Announces Fourth-Quarter 2019 Results
Jan 27, 2020
Exact Sciences schedules fourth-quarter, full-year 2019 earnings call
Dec 12, 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
Dec 04, 2019
Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors
Nov 26, 2019
Exact Sciences to participate in December investor conference
Nov 08, 2019
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
Nov 01, 2019
Exact Sciences to participate in November investor conferences
Oct 29, 2019
Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study
Oct 29, 2019
Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million
Oct 08, 2019
Exact Sciences schedules third-quarter 2019 earnings call